{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hamer MJ"],"funding":["National Institute of Allergy and Infectious Diseases","Intramural NIH HHS","National Institutes of Health"],"pagination":["294-302"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10127441"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["401(10373)"],"pubmed_abstract":["<h4>Background</h4>WHO has identified Marburg virus as an emerging virus requiring urgent vaccine research and development, particularly due to its recent emergence in Ghana. We report results from a first-in-human clinical trial evaluating a replication-deficient recombinant chimpanzee adenovirus type 3 (cAd3)-vectored vaccine encoding a wild-type Marburg virus Angola glycoprotein (cAd3-Marburg) in healthy adults.<h4>Methods</h4>We did a first-in-human, phase 1, open-label, dose-escalation trial of the cAd3-Marburg vaccine at the Walter Reed Army Institute of Research Clinical Trials Center in the USA. Healthy adults aged 18-50 years were assigned to receive a single intramuscular dose of cAd3-Marburg vaccine at either 1 × 10<sup>10</sup> or 1 × 10<sup>11</sup> particle units (pu). Primar"],"journal":["Lancet (London, England)"],"pubmed_title":["Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial."],"pmcid":["PMC10127441"],"funding_grant_id":["Z99 AI999999"],"pubmed_authors":["Hickman S","Murray T","Schech S","Trofymenko O","Wilson H","Scott PT","Strom L","Coates EE","Ploquin A","Costner P","Gordon IJ","Amare MF","Kioko V","Larkin B","O'Connell S","Gall JG","Sullivan NJ","Hamer MJ","McCauley MD","Widge AT","Lampley R","Dulan CNM","McDermott AB","Preston A","RV 507 Study Team","Ledgerwood JE","Houser KV","Basappa M","Waterman PE","Flach B","Stanley DA","Andrews C","Narpala SR","Read M","Padilla M","Gaudinski MR","Lee C","Augustine B","Koup RA","Cox JH","Swanson PA","Hofstetter AR","Vazquez S","Ake JA","Storme C","Holman LA","Modjarrad K","Mascola JR","Ortega-Villa AM","Hunegnaw R","Robb ML","Yamshchikov GV","Hutter JN","Thillainathan J","Morgan P","Happe M"],"additional_accession":[]},"is_claimable":false,"name":"Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.","description":"<h4>Background</h4>WHO has identified Marburg virus as an emerging virus requiring urgent vaccine research and development, particularly due to its recent emergence in Ghana. We report results from a first-in-human clinical trial evaluating a replication-deficient recombinant chimpanzee adenovirus type 3 (cAd3)-vectored vaccine encoding a wild-type Marburg virus Angola glycoprotein (cAd3-Marburg) in healthy adults.<h4>Methods</h4>We did a first-in-human, phase 1, open-label, dose-escalation trial of the cAd3-Marburg vaccine at the Walter Reed Army Institute of Research Clinical Trials Center in the USA. Healthy adults aged 18-50 years were assigned to receive a single intramuscular dose of cAd3-Marburg vaccine at either 1 × 10<sup>10</sup> or 1 × 10<sup>11</sup> particle units (pu). Primar","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2026-06-02T06:12:41.119Z","creation":"2024-11-12T22:32:29.008Z"},"accession":"S-EPMC10127441","cross_references":{"pubmed":["36709074"],"doi":["10.1016/S0140-6736(22)02400-X","10.1016/s0140-6736(22)02400-x"]}}